Area of leased property (sqft) Area of Real Estate Property Filing of the first MAA - first indication Filing of M M A [Member] Filing of M M A Document Type Document Type Disqualifying dispositions of incentive stock options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Disqualifying Dispositions Of Incentive Stock Options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Disqualifying Dispositions Of Incentive Stock Options ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Aggregate intrinsic value, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other (expense) income, net Other Nonoperating Income (Expense) Other comprehensive (loss) income: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Research and development tax incentive credit received during the period Research And Development Tax Incentive Credit Received During Period Research And Development Tax Incentive Credit Received During Period Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Employee Benefit Plan Retirement Benefits [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Proceeds from issuance of common stock, upon the exercise of warrants Proceeds from Warrant Exercises Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Security Exchange Name Security Exchange Name Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current Future minimum annual cash obligations, next 12 months Other Commitment, to be Paid, Year One Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accrued professional fees Accrued Professional Fees, Current Long-term investments Debt Securities, Available-for-sale, Noncurrent ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Subsidiaries Subsidiaries [Member] Entity Address, State or Province Entity Address, State or Province Expected income tax benefit at federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating ROU assets Operating Lease, Right-of-Use Asset Lease termination term Lessee, Operating Lease, Lease Not yet Commenced, One Time Option to Terminate, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, One Time Option to Terminate, Expiration Period Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Stock options (in shares) Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Monthly base rate (usd per sqft) Rent Per Square Foot Rent Per Square Foot New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Schedule of ROU Assets and Lease Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Research tax credit carryforwards Tax Credit Carryforward, Amount Stockholders' Equity, Beginning Balance (in shares) Stockholders' Equity, Ending Balance (in shares) Shares, Outstanding Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2020 and December 31, 2019, respectively Preferred Stock, Value, Issued Income Taxes Income Tax, Policy [Policy Text Block] Remaining maturity Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Long-lived asset impairment charges Tangible Asset Impairment Charges Total operating expenses Operating Expenses Employer match, maximum contributions Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Stock options exercisable, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Maximum milestone payments per target Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Forfeitures and cancellations (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeitures and cancellations (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Award expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Statement [Line Items] Statement [Line Items] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Net loss per common share: Earnings Per Share, Basic and Diluted [Abstract] Tax Period [Axis] Tax Period [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Entity Voluntary Filers Entity Voluntary Filers Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Agency securities US Government Agencies Debt Securities [Member] Interest income Interest Income, Other Foreign tax authority Foreign Tax Authority [Member] Short Term and Long Term Investments Marketable Securities, Policy [Policy Text Block] Basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Entity Small Business Entity Small Business Basis of Consolidation Consolidation, Policy [Policy Text Block] Revenue Recognition [Abstract] Revenue Recognition [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Notes Payable Debt Disclosure [Text Block] Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Weighted average remaining contractual term, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Collaborative Research and Development Agreement Collaborative Arrangement [Member] Proceeds from public offerings, net of underwriters' fees Proceeds, net of underwriters' fees Proceeds from Issuance of Common Stock Loss on disposal of property and equipment, net of gain on lease termination Loss On Disposal Of Property And Equipment, Net Of Gain On Lease Termination Loss On Disposal Of Property And Equipment, Net Of Gain On Lease Termination Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Amendment Flag Amendment Flag Prepaid rent Prepaid Rent Stock-based compensation Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Deferred Tax Assets: Deferred Tax Assets, Gross [Abstract] Shares reserved for future award grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Short-term investments Debt Securities, Available-for-sale, Current Financial Instruments [Domain] Financial Instruments [Domain] Fair Value of Other Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Standby Letters of Credit Standby Letters of Credit [Member] Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Subsequent Event Subsequent Events [Text Block] Change in the valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Employee Stock Employee Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Stock-based compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Anti-PD-1 (CC-90006) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two State tax authority State and Local Jurisdiction [Member] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Available-for-sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Costs in Cash Flow Statement Lease, Cost [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other long-term assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Shares issued for public offerings, net of underwriters' fees Stock Issued During Period, Value, New Issues Total assets Assets Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Scenario [Axis] Scenario [Axis] Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Research and development Research And Development Tax Incentive Credit Research And Development Tax Incentive Credit Weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Income tax expense related to other comprehensive income OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Interest expense Interest Expense Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Depreciation and amortization Depreciation, Depletion and Amortization Equity compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Reconciliation of Expected Statutory Federal Income Tax Provision and Actual Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Product and Service [Axis] Product and Service [Axis] Aggregate draw on term loan Proceeds from Notes Payable Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Phase 1 clinical trial initiation Phase 1 Clinical Trial Initiation [Member] Phase 1 Clinical Trial Initiation [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest or penalties on uncertain tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Australian tax incentive receivable Research And Development Tax Incentive Credit Receivable, Current Research And Development Tax Incentive Credit Receivable, Current Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash payments under licensing agreements Payments For Upfront, Milestone, And Royalty Payments Payments For Upfront, Milestone, And Royalty Payments Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Subsequent event Subsequent Event [Member] Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Federal tax authority Domestic Tax Authority [Member] Notes Payable to Banks Notes Payable to Banks [Member] BMS Bristo-Meyers Squibb [Member] Bristo-Meyers Squibb [Member] Letters of credit outstanding Letters of Credit Outstanding, Amount Common stock, shares authorized (in shares) Common Stock, Shares Authorized Licensing agreement, remaining life Collaboration License Agreement, Maximum Term Collaboration License Agreement, Maximum Term Property and equipment, gross Property, Plant and Equipment, Gross Proceeds from issuance of common stock, upon the exercise of stock options Proceeds from Stock Options Exercised Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Permanent items Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Number of banks utilized for diversification of funds (in banks) Number Of Financial Institutions Utilized For Diversification Of Funds Number Of Financial Institutions Utilized For Diversification Of Funds Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Term Loans Term Loans [Member] Term Loans [Member] Operating lease liabilities Operating Lease, Liability, Noncurrent Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Underwriters' option Over-Allotment Option [Member] Return to provision adjustment Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Current assets: Assets, Current [Abstract] Income Tax Authority [Domain] Income Tax Authority [Domain] Excess tax benefits associated with the exercise of non-qualified stock options Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation [Member] Phase 3 Clinical Trial Initiation [Member] Consolidated Entities [Axis] Consolidated Entities [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Agreement term following first commercial sale or expiration of the last to expire patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Scenario [Domain] Scenario [Domain] Debt instrument, maximum borrowing capacity Debt Instrument, Maximum Borrowing Capacity Debt Instrument, Maximum Borrowing Capacity Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Allowance for credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss Australian Taxation Office Australian Taxation Office [Member] Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Director Director [Member] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Security deposit Security Deposit Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Summary of Non-cash Stock-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Cover [Abstract] Cover [Abstract] Warrants exercised Stock Issued During Period, Value, Due To Warrants Exercised Stock Issued During Period, Value, Due To Warrants Exercised Employer match, percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Phase 3 clinical trial initiation - second indication Phase 3 clinical trial initiation - second indication [Domain] Phase 3 clinical trial initiation - second indication [Domain] Lease renewal term Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Components of Income/(Loss) before Income Tax Provision (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Property and equipment, useful life Property, Plant and Equipment, Useful Life Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Accretion/amortization of investments, net Accretion (Amortization) of Discounts and Premiums, Investments Warrants exercised (in shares) Stock Issued During Period, Shares, Due To Warrants Exercised Stock Issued During Period, Shares, Due To Warrants Exercised Annual increase in number of shares available for issuance Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net Total Fair Value Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total deferred tax assets Deferred Tax Assets, Gross Minimum Minimum [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Final payment fee Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Operating lease liabilities Operating Lease, Liability, Current Payments on notes payable Repayments of Notes Payable Future minimum annual cash obligations, thereafter Other Commitments, Due After Year One Other Commitments, Due After Year One Accrued research and development expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Summary of Weighted Average Assumptions in Stock Option Valuations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Employer match, percent of contributions Defined Contribution Plan, Employer Matching Contribution, Percent of Match Entity Interactive Data Current Entity Interactive Data Current Number of loan installments (in installments) Debt Instrument, Number Of Loan Installments Debt Instrument, Number Of Loan Installments Exercises (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Activity Related to Stock Option Awards Share-based Payment Arrangement, Option, Activity [Table Text Block] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Total deferred tax liabilities Deferred Tax Liabilities, Gross TESARO TESARO, Inc. And TESARO Development, Inc. [Member] TESARO, Inc. And TESARO Development, Inc. [Member] Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of reportable segments Number of Reportable Segments Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Filing of the first NDA - first indication Filing of N D A [Member] Filing of N D A Research and development Research and Development Expense [Member] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Research and development expenditure Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Other, net Deferred Tax Assets, Other Royalty percent on net sales Net Sales Royalty Percent Net Sales Royalty Percent Share price (in dollars per share) Shares Issued, Price Per Share Employee and Nonemployee Stock Options Employee And Nonemployee Stock Options [Member] Employee And Nonemployee Stock Options [Member] Deferred Tax Liabilities: Components of Deferred Tax Liabilities [Abstract] Net operating loss carryforward, utilization limitation Operating Loss Carryforwards, Limitations On Use, Amount Operating Loss Carryforwards, Limitations On Use, Amount Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Term B and Term C Loans Term B Loans And Term C Loans [Member] Term B Loans And Term C Loans [Member] Foreign Currency of Foreign Operations Foreign Currency Transactions and Translations Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Unrealized losses on available-for-sale Debt Securities, Available-for-sale, Unrealized Loss Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Loan and Security Agreement (LSA) Loan And Security Agreement [Member] Loan And Security Agreement [Member] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Class of Warrant or Right [Table] Class of Warrant or Right [Table] Income taxes Increase (Decrease) in Income Taxes Payable Other income (expense), net: Nonoperating Income (Expense) [Abstract] Aggregate borrowing capacity Debt Instrument, Face Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] License agreement, obligation payable period Collaboration License Agreement, Obligation Payable Period Collaboration License Agreement, Obligation Payable Period License costs Collaboration License Agreement, Upfront, Milestone And Royalty Expense Collaboration License Agreement, Upfront, Milestone And Royalty Expense General and administrative General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Total offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Credit Facility [Domain] Credit Facility [Domain] Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member] AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member] Mutual funds Mutual Fund [Member] Unrecognized tax benefits that if recognized and realized would affect the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Balance at the beginning of the year Balance at the end of the year Unrecognized Tax Benefits Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Weighted-average number of shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock, $0.001 par value, 500,000 shares authorized, 27,356 shares and 27,255 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Document Annual Report Document Annual Report Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Current Reporting Status Entity Current Reporting Status Retirement Benefits [Abstract] Retirement Benefits [Abstract] Subsequent Event [Table] Subsequent Event [Table] Acquisition of investments Payments to Acquire Debt Securities, Available-for-sale Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Increase in annual rent Annual Rent Increase Percent Annual Rent Increase Percent Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value 2017 Equity Incentive Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Present value of lease liabilities Operating Lease, Liability Debt Instrument [Line Items] Debt Instrument [Line Items] Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Total stockholders’ equity Stockholders' Equity, Beginning Balance Stockholders' Equity, Ending Balance Stockholders' Equity Attributable to Parent Collaboration And Exclusive License Agreement Collaboration And Exclusive License Agreement [Member] Collaboration And Exclusive License Agreement Description of the Business Nature of Operations [Text Block] Payments for offering costs, net Payments of Stock Issuance Costs Rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Lease Arrangement [Domain] Lease Arrangement [Domain] [Domain] for Lease Arrangement [Axis] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member] AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member] Operating leases, rent expense Operating Leases, Rent Expense, Net Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Australia Research and Development Tax Incentive Income Taxes Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accrued compensation and related expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease cost Operating Lease, Cost 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Refundable AMT credit Effective Income Tax Rate Reconciliation, Alternative Minimum Tax Effective Income Tax Rate Reconciliation, Alternative Minimum Tax Non-cash interest expense Other Noncash Income (Expense) Loss on disposal of tenant improvements and certain equipment Gain (Loss) on Disposition of Property Plant Equipment Increase related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increase related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Net deferred tax assets Deferred Tax Assets, Net, Before Valuation Allowance Deferred Tax Assets, Net, Before Valuation Allowance Equity Component [Domain] Equity Component [Domain] 2017 Employee Stock Purchase Plan Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Less: valuation allowance Deferred Tax Assets, Valuation Allowance Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Equity Incentive Plans Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other current liabilities Other Liabilities, Current Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Net operating loss carryforwards Operating Loss Carryforwards Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Shares Subject to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Unrecognized compensation cost Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Lease term Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Certificates of deposit Certificates of Deposit [Member] Long Lived Assets Property, Plant and Equipment, Impairment [Policy Text Block] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Property and Equipment Property, Plant and Equipment [Table Text Block] US Treasury Securities US Treasury Securities [Member] Shares issued for public offerings, net of underwriters' fees (in shares) Common shares issued (in shares) Stock Issued During Period, Shares, New Issues Leasehold improvements Leasehold Improvements [Member] Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Fixed interest rate Debt Instrument, Interest Rate, Stated Percentage Money market funds Money Market Funds [Member] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Shares issued under employee stock plans (in shares) Exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income (expense), net Nonoperating Income (Expense) Unrealized (loss) income on available for sale securities, net of tax of $0, $153, and $55, respectively OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Subsequent Events [Abstract] Milestone payment earned Revenue Recognized, Milestone Method, Milestone Payment Earned Revenue Recognized, Milestone Method, Milestone Payment Earned Sale of Stock [Domain] Sale of Stock [Domain] 2018 and after Tax Year 2018 and After [Member] Tax Year 2018 and After Carrying Amount Reported Value Measurement [Member] U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Plan Name [Domain] Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Tax Period [Domain] Tax Period [Domain] Additional paid in capital Additional Paid in Capital Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Provision for income taxes Income tax benefit Income Tax Expense (Benefit) Milestones achieved during period, amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Refundable tax incentive for qualified research and development activities Research And Development Tax Incentive Credit, Percentage Research And Development Tax Incentive Credit, Percentage Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Employer contributions to the plan Defined Contribution Plan, Employer Discretionary Contribution Amount Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Title of Individual [Domain] Title of Individual [Domain] Accrued expenses Total accrued expenses Accrued Liabilities, Current Local Phone Number Local Phone Number Schedule of Activity Related to Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Address, Address Line One Entity Address, Address Line One Anti-PD-1 (GSK4057190A/Dostarlimab) AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Shares issued under employee stock plans Stock Issued During Period, Value, Stock Options Exercised Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Award Type [Axis] Award Type [Axis] Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Equity compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Term A Loans Term A Loans [Member] Term A Loans [Member] Restricted cash Restricted Cash Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Australian tax incentive receivable Increase (Decrease) in Income Taxes Receivable Weighted average period remaining for amortization of unrecognized compensation cost Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Tax credit carryforward, utilization limitation Tax Credit Carryforward, Limitations On Use, Amount Tax Credit Carryforward, Limitations On Use, Amount Award Type [Domain] Award Type [Domain] Trading Symbol Trading Symbol Stock options exercisable, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Notes payable, current portion Notes Payable, Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Notes payable Notes Payable, Fair Value Disclosure Office furniture and equipment Office Equipment [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Entity Shell Company Entity Shell Company Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Schedule of Unrealized Loss and Fair Values in a Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Accounting Pronouncements Recently Adopted New Accounting Pronouncements, Policy [Policy Text Block] Entity Public Float Entity Public Float Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Completion of first in vivo toxicology studies using GLPs In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member]